<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31383794</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1754-8411</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Disease models &amp; mechanisms</Title><ISOAbbreviation>Dis Model Mech</ISOAbbreviation></Journal><ArticleTitle>Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dmm040238</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1242/dmm.040238</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) presents a poorly understood pathogenesis. Evidence from patients and mutant SOD1 mouse models suggests vascular damage may precede or aggravate motor dysfunction in ALS. We have previously shown angiogenin (ANG) treatment enhances motor neuron survival, delays motor dysfunction and prevents vascular regression in the SOD1<sup>G93A</sup> ALS model. However, the existence of vascular defects at different stages of disease progression remains to be established in other ALS models. Here, we assessed vascular integrity <i>in vivo</i> throughout different disease stages, and investigated whether ANG treatment reverses vascular regression and prolongs motor neuron survival in the FUS (1-359) mouse model of ALS. Lumbar spinal cord tissue was collected from FUS (1-359) and non-transgenic control mice at postnatal day (P)50, P90 and P120. We found a significant decrease in vascular network density in lumbar spinal cords from FUS (1-359) mice by day 90, at which point motor neuron numbers were unaffected. ANG treatment did not affect survival or counter vascular regression. Endogenous <i>Ang1</i> and <i>Vegf</i> expression were unchanged at P50 and P90; however, we found a significant decrease in miRNA 126 at P50, indicating vascular integrity in FUS mice may be compromised via an alternative pathway. Our study demonstrates that vascular regression occurs before motor neuron degeneration in FUS (1-359) mice, and highlights that heterogeneity in responses to novel ALS therapeutics can already be detected in preclinical mouse models of ALS.This article has an associated First Person interview with the joint first authors of the paper.</AbstractText><CopyrightInformation>&#xa9; 2019. Published by The Company of Biologists Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crivello</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9535-7595</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogg</LastName><ForeName>Marion C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-2815-8761</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FutureNeuro Research Centre, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jirstr&#xf6;m</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FutureNeuro Research Centre, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halang</LastName><ForeName>Luise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rayner</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coughlan</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>Sebastian A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Tissue Biology Laboratory, Department of Medical Biochemistry and Biophysics, Center for Molecular Medicine, Karolinska Institute, Scheeles v. 2, 17177 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland prehn@rcsi.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prehn</LastName><ForeName>Jochen H M</ForeName><Initials>JHM</Initials><Identifier Source="ORCID">0000-0003-3479-7794</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Medical Physics, Centre for the Study of Neurological Disorders, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FutureNeuro Research Centre, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dis Model Mech</MedlineTA><NlmUniqueID>101483332</NlmUniqueID><ISSNLinking>1754-8403</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599551">FUS protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545201">MIRN126 microRNA, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C001643">podocalyxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.27.-</RegistryNumber><NameOfSubstance UI="C046366">angiogenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.27.5</RegistryNumber><NameOfSubstance UI="D012259">Ribonuclease, Pancreatic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Dis Model Mech. 2020 May 15;13(5):</RefSource><PMID Version="1">32482632</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012259" MajorTopicYN="N">Ribonuclease, Pancreatic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012795" MajorTopicYN="N">Sialoglycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Angiogenin</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">Motoneuron</Keyword><Keyword MajorTopicYN="N">Vascular defects</Keyword></KeywordList><CoiStatement>Competing interestsJ.H.M.P. is a beneficiary of patents relating to the use of angiogenin for the treatment of CNS diseases.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31383794</ArticleId><ArticleId IdType="pmc">PMC6737946</ArticleId><ArticleId IdType="doi">10.1242/dmm.040238</ArticleId><ArticleId IdType="pii">dmm.040238</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alliegro M. C. and Alliegro M. A. (1996). A nuclear protein regulated during the transition from active to quiescent phenotype in cultured endothelial cells. Dev. Biol. 174, 288-297. 10.1006/dbio.1996.0074</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.1996.0074</ArticleId><ArticleId IdType="pubmed">8631501</ArticleId></ArticleIdList></Reference><Reference><Citation>Alliegro M. C. and Alliegro M. A. (2002). Nuclear injection of anti-pigpen antibodies inhibits endothelial cell division. J. Biol. Chem. 277, 19037-19041. 10.1074/jbc.M200737200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M200737200</ArticleId><ArticleId IdType="pubmed">11886863</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson M. K., St&#xe5;hlberg A., Arvidsson Y., Olofsson A., Semb H., Stenman G., Nilsson O. and &#xc5;man P. (2008). The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 9, 37 10.1186/1471-2121-9-37</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-9-37</ArticleId><ArticleId IdType="pmc">PMC2478660</ArticleId><ArticleId IdType="pubmed">18620564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A. and Traynor B. J. (2018). Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 17, 94-102. 10.1016/S1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B. G. and On Behalf Of The Eurals Consortium (2009). Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 10, 310-323. 10.3109/17482960802566824</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan K. S., Mitchem M. R., Hogg M. C. and Prehn J. H. M. (2015). &#x201c;Preconditioning&#x201d; with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol. Aging 36, 1140-1150. 10.1016/j.neurobiolaging.2014.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.022</ArticleId><ArticleId IdType="pubmed">25443289</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivello M., O'Riordan S. L., Woods I., Cannon S., Halang L., Coughlan K. S., Lewandowski S. A. and Prehn J. H. M. (2018). Pleiotropic activity of systemically delivered angiogenin in the SOD1(G93A) mouse model. Neuropharmacology 133, 503-511. 10.1016/j.neuropharm.2018.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2018.02.022</ArticleId><ArticleId IdType="pubmed">29486168</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy A., Kalmar B., Stewart M., Park H., Burke B., Noy S. J., Redhead Y., Humphrey J., Lo K., Jaeger J. et al. (2017). Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in &#x2018;FUSDelta14&#x2019; knockin mice. Brain 140, 2797-2805. 10.1093/brain/awx248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx248</ArticleId><ArticleId IdType="pmc">PMC5841203</ArticleId><ArticleId IdType="pubmed">29053787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D. and Haass C. (2013). Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration. Mol. Cell. Neurosci. 56, 475-486. 10.1016/j.mcn.2013.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.03.006</ArticleId><ArticleId IdType="pubmed">23557964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish J. E., Santoro M. M., Morton S. U., Yu S., Yeh R. F., Wythe J. D., Ivey K. N., Bruneau B. G., Stainier D. Y. R., Srivastava D. et al. (2008). miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15, 272-284. 10.1016/j.devcel.2008.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2008.07.008</ArticleId><ArticleId IdType="pmc">PMC2604134</ArticleId><ArticleId IdType="pubmed">18694566</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujioka Y., Ishigaki S., Masuda A., Iguchi Y., Udagawa T., Watanabe H., Katsuno M., Ohno K., Sobue G. (2013). FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD. Sci. Rep. 3, 2388 10.1038/srep02388</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep02388</ArticleId><ArticleId IdType="pmc">PMC3737506</ArticleId><ArticleId IdType="pubmed">23925123</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Rodrigues M. C. O., Hernandez-Ontiveros D. G., Louis M. K., Willing A. E. and Borlongan C. V. (2011). Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 1398, 113-125. 10.1016/j.brainres.2011.04.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.04.049</ArticleId><ArticleId IdType="pubmed">21632035</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenway M. J., Andersen P. M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J. et al. (2006). ANG mutations segregate with familial and &#x2018;sporadic&#x2019; amyotrophic lateral sclerosis. Nat. Genet. 38, 411-413. 10.1038/ng1742</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1742</ArticleId><ArticleId IdType="pubmed">16501576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt C., Kirby J., Highley J. R., Hartley J. A., Hibberd R., Hollinger H. C., Williams T. L., Ince P. G., Mcdermott C. J., Shaw P. J. et al. (2010). Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 67, 455-461. 10.1001/archneurol.2010.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.52</ArticleId><ArticleId IdType="pubmed">20385912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg M. C., Halang L., Woods I., Coughlan K. S. and Prehn J. H. M. (2018). Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph Lateral Scler Frontotemporal Degener 19, 438-445. 10.1080/21678421.2017.1407796</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1407796</ArticleId><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaluddin M. S., Weakley S. M., Zhang L., Kougias P., Lin P. H., Yao Q. and Chen C. (2011). miRNAs: roles and clinical applications in vascular disease. Expert Rev. Mol. Diagn. 11, 79-89. 10.1586/erm.10.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erm.10.103</ArticleId><ArticleId IdType="pmc">PMC3077058</ArticleId><ArticleId IdType="pubmed">21171923</ArticleId></ArticleIdList></Reference><Reference><Citation>Keifer O. P. Jr., O'connor D. M. and Boulis N. M. (2014). Gene and protein therapies utilizing VEGF for ALS. Pharmacol. Ther. 141, 261-271. 10.1016/j.pharmthera.2013.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.10.009</ArticleId><ArticleId IdType="pmc">PMC4659499</ArticleId><ArticleId IdType="pubmed">24177067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D., Sebastia J., Greenway M. J., King M. A., Connaughton D., Concannon C. G., Fenner B., Hardiman O. and Prehn J. H. M. (2008). Control of motoneuron survival by angiogenin. J. Neurosci. 28, 14056-14061. 10.1523/JNEUROSCI.3399-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3399-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671464</ArticleId><ArticleId IdType="pubmed">19109488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M. and Cleveland D. W. (2010). TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 19, R46-R64. 10.1093/hmg/ddq137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M., Hutt K. R., Vu A. Q., Baughn M., Huelga S. C., Clutario K. M., Ling S.-C., Liang T. Y., Mazur C. et al. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488-1497. 10.1038/nn.3230</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3230</ArticleId><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski S. A., Nilsson I., Fredriksson L., Lonnerberg P., Muhl L., Zeitelhofer M., Adzemovic M. Z., Nichterwitz S., Lawrence D. A., Hedlund E. et al. (2016). Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. Acta Neuropathol. 131, 453-464. 10.1007/s00401-015-1520-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1520-2</ArticleId><ArticleId IdType="pmc">PMC4839168</ArticleId><ArticleId IdType="pubmed">26687981</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K. J. and Schmittgen T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408. 10.1006/meth.2001.1262</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Zheng L., Viera L., Suswam E., Li Y., Li X., Estevez A. G. and King P. H. (2007). Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J. Neurosci. 27, 7929-7938. 10.1523/JNEUROSCI.1877-07.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1877-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672720</ArticleId><ArticleId IdType="pubmed">17652584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A. C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J. P., Mead R., Niessen H. G., Petri S., Pradat P.-F. et al. (2010). Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 11, 38-45. 10.3109/17482960903545334</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimon R., Ionescu A., Bonnie A., Sweetat S., Wald-Altman S., Inbar S., Gradus T., Trotti D., Weil M., Behar O. et al. (2018). miR126-5p Downregulation Facilitates Axon Degeneration and NMJ Disruption via a Non-Cell-Autonomous Mechanism in ALS. J. Neurosci. 38, 5478-5494. 10.1523/JNEUROSCI.3037-17.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3037-17.2018</ArticleId><ArticleId IdType="pmc">PMC6001038</ArticleId><ArticleId IdType="pubmed">29773756</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M., Talbot K. and Ansorge O. (2016). Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathol Commun. 4, 99 10.1186/s40478-016-0358-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0358-8</ArticleId><ArticleId IdType="pmc">PMC5011941</ArticleId><ArticleId IdType="pubmed">27600654</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A. and Hermine O. (2017). ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front. Aging Neurosci. 9, 68 10.3389/fnagi.2017.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Valdmanis P. N., Gould P. V., Julien J. P. and Dupre N. (2016). From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun. 4, 70 10.1186/s40478-016-0340-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A. C., Pinto S. and de Carvalho M. (2014). Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. Biomed Res Int. 2014, 947513 10.1155/2014/947513</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/947513</ArticleId><ArticleId IdType="pmc">PMC4022172</ArticleId><ArticleId IdType="pubmed">24987705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E., Messina P., Logroscino G., Beghi E. and Group S. (2014). Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann. Neurol. 75, 287-297. 10.1002/ana.24096</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24096</ArticleId><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Stewart H., Dejesus-Hernandez M., Krieger C., Graff-Radford N., Fabros M., Briemberg H., Cashman N., Eisen A., Mackenzie I. R. A. et al. &#xa0;(2010). Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle Nerve. 42, 170-176. 10.1002/mus.21665</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21665</ArticleId><ArticleId IdType="pmc">PMC2969843</ArticleId><ArticleId IdType="pubmed">20544928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J., Appel S., Baloh R. H., Barohn R., Brooks B. R., Elman L., Floeter M. K., Henderson C., Lomen-Hoerth C., Macklis J. D. et al. (2013). Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 14, 5-18. 10.3109/21678421.2013.778548</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.778548</ArticleId><ArticleId IdType="pmc">PMC3779649</ArticleId><ArticleId IdType="pubmed">23678876</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W. and Philips T. (2013). The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248-264. 10.1038/nrn3430</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J. D. (2017). Edaravone: a new drug approved for ALS. Cell 171, 725 10.1016/j.cell.2017.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Rule R. R., Schuff N., Miller R. G. and Weiner M. W. (2010). Gray matter perfusion correlates with disease severity in ALS. Neurology 74, 821-827. 10.1212/WNL.0b013e3181d3e2dd</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181d3e2dd</ArticleId><ArticleId IdType="pmc">PMC2839193</ArticleId><ArticleId IdType="pubmed">20147656</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J., Oussini H. E., Mersmann S., Drenner K., Wagner M., Sun Y., Allmeroth K., Dieterl&#xe9; S., Sinniger J., Dirrig-Grosch S. et al. (2017). Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathol. 133, 887-906. 10.1007/s00401-017-1687-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1687-9</ArticleId><ArticleId IdType="pmc">PMC5427169</ArticleId><ArticleId IdType="pubmed">28243725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schober A., Nazari-Jahantigh M., Wei Y., Bidzhekov K., Gremse F., Grommes J., Megens R. T. A., Heyll K., Noels H., Hristov M. et al. (2014). MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med. 20, 368-376. 10.1038/nm.3487</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3487</ArticleId><ArticleId IdType="pmc">PMC4398028</ArticleId><ArticleId IdType="pubmed">24584117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastia J., Kieran D., Breen B., King M. A., Netteland D. F., Joyce D., Fitzpatrick S. F., Taylor C. T. and Prehn J. H. M. (2009). Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ. 16, 1238-1247. 10.1038/cdd.2009.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2009.52</ArticleId><ArticleId IdType="pubmed">19444281</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova T. A., Peters O. M., Deykin A. V., Connor-Robson N., Robinson H., Ustyugov A. A., Bachurin S. O., Ermolkevich T. G., Goldman I. L., Sadchikova E. R. et al. (2013). Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J. Biol. Chem. 288, 25266-25274. 10.1074/jbc.M113.492017</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.492017</ArticleId><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Kisler K., Montagne A., Toga A. W. and Zlokovic B. V. (2018). The role of brain vasculature in neurodegenerative disorders. Nat. Neurosci. 21, 1318-1331. 10.1038/s41593-018-0234-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0234-x</ArticleId><ArticleId IdType="pmc">PMC6198802</ArticleId><ArticleId IdType="pubmed">30250261</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Zhao Z., Montagne A., Nelson A. R. and Zlokovic B. V. (2019). Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21-78. 10.1152/physrev.00050.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00050.2017</ArticleId><ArticleId IdType="pmc">PMC6335099</ArticleId><ArticleId IdType="pubmed">30280653</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M. R., Hardiman O., Benatar M., Brooks B. R., Chio A., de Carvalho M., Ince P. G., Lin C., Miller R. G., Mitsumoto H. et al. (2013). Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12, 310-322. 10.1016/S1474-4422(13)70036-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70036-X</ArticleId><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es M. A., Diekstra F. P., Veldink J. H., Baas F., Bourque P. R., Schelhaas H. J., Strengman E., Hennekam E. A. M., Lindhout D., Ophoff R. A. et al. (2009). A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 72, 287-288. 10.1212/01.wnl.0000339487.84908.00</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000339487.84908.00</ArticleId><ArticleId IdType="pubmed">19153377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Aurora A. B., Johnson B. A., Qi X., Mcanally J., Hill J. A., Richardson J. A., Bassel-Duby R. and Olson E. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261-271. 10.1016/j.devcel.2008.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2008.07.002</ArticleId><ArticleId IdType="pmc">PMC2685763</ArticleId><ArticleId IdType="pubmed">18694565</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E. A., Sengillo J. D., Sullivan J. S., Henkel J. S., Appel S. H. and Zlokovic B. V. (2013). Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 125, 111-120. 10.1007/s00401-012-1039-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E. A., Sengillo J. D., Sagare A. P., Zhao Z., Ma Q., Zuniga E., Wang Y., Zhong Z., Sullivan J. S., Griffin J. H. et al. (2014). Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. USA. 111, E1035-E1042. 10.1073/pnas.1401595111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401595111</ArticleId><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Yu W., Kishikawa H., Folkerth R. D., Iafrate A. J., Shen Y., Xin W., Sims K., Hu G. (2007). Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62, 609-617. 10.1002/ana.21221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21221</ArticleId><ArticleId IdType="pmc">PMC2776820</ArticleId><ArticleId IdType="pubmed">17886298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki S., Ivanov P., Hu G. F. and Anderson P. (2009). Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol. 185, 35-42. 10.1083/jcb.200811106</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200811106</ArticleId><ArticleId IdType="pmc">PMC2700517</ArticleId><ArticleId IdType="pubmed">19332886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T., Sato Y., Morita I. and Abe M. (2010). Pigpen, a nuclear coiled body component protein, is involved in angiogenesis. Cancer Sci. 101, 1170-1176. 10.1111/j.1349-7006.2010.01494.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2010.01494.x</ArticleId><ArticleId IdType="pubmed">20148893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Wu Y. C., Mullane P., Ji Y. J., Liu H., He L., Arora A., Hwang H.-Y., Alessi A. F., Niaki A. G. et al. (2018). FUS regulates activity of microRNA-mediated gene silencing. Mol. Cell 69, 787-801.e8. 10.1016/j.molcel.2018.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.02.001</ArticleId><ArticleId IdType="pmc">PMC5836505</ArticleId><ArticleId IdType="pubmed">29499134</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z., Deane R., Ali Z., Parisi M., Shapovalov Y., O'banion M. K., Stojanovic K., Sagare A., Boillee S., Cleveland D. W. et al. (2008). ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 11, 420-422. 10.1038/nn2073</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>